BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Phase 1

Completed

• Conditions: Neoplasms
• Interventions: Drug: Copanlisib (Aliqopa, BAY80-6946)

• Registration Number: NCT00962611
• Lead Sponsor: Bayer

Brief Summary

The purpose of this study is to determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study First Submitted: 2009-08-19
• Study First Submitted QC: 2009-08-19
• Study First Posted: 2009-08-20
• Study Start: 2009-11-19
• Primary Completion: 2016-02-23
• Study Completion: 2016-02-23
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-05
• Last Update Posted: 2017-10-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 57

Inclusion Criteria

• Age >/= 18 years.
• Histological or cytological documentation of non-hematologic, malignant solid tumor, excluding primary brain or spinal tumors, or history of central nervous system metastases
• At least one measurable lesion or evaluable disease
• Life expectancy of at least 12 weeks
• ECOG Performance Status of 0, 1 or 2
• PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists]. Low-dose aspirin is permitted (</= 100 mg daily).
• Adequate bone marrow, liver and renal function
• Ability to understand and to sign an informed consent form; a signed informed consent must be obtained prior to any study specific procedures

Read More

Exclusion Criteria

• History of cardiac disease congestive heart failure (CHF) > NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset angina within 3 months prior to study entry or unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or Digoxin are permitted).
• Current diagnosis of type I or II diabetes mellitus or fasting blood glucose level >125 mg/dL at screening, or HbA1c 7%
• Active clinically serious infections > Grade 2 (NCI-CTCAE Version 3.0)
• History of having received allogeneic organ transplant
• Uncontrolled seizure disorder. Use of cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or phenobarbital) is not allowed throughout the entire study.
• Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Copanlisib	Copanlisib (Aliqopa, BAY80-6946)	-

Primary Outcome Measures

Name	Time	Method
Characterize safety, tolerability + pharmacokinetics, to determine the maximum tolerated dose of BAY80-6946 administered 1x weekly for 3 weeks, every 4weeks, as a 1h-intravenous infusion. Evaluate biomarkers that may be predictive of tumor response.	2 years

Secondary Outcome Measures

Name	Time	Method
Evaluate for early signs of efficacy in expansion cohorts	2 years
Determine the effects of BAY80-6946 on blood glucose and insulin, and its safety in patients with type I or II diabetes.	2 years